There were about 58 million cases of trichomoniasis in 2013.[38] It is more common in women (2.7%) than males (1.4%).[39] It is the most common non-viral STI in the U.S., with an estimated 3.7 million prevalent cases and 1.1 million new cases per year.[40][41] It is estimated that 3% of the general U.S. population is infected,[21][42] and 7.5-32% of moderate-to-high risk (including incarcerated) populations.[43][44][45][46][47][48][49][50]
^ Munson E, Kramme T, Napierala M, Munson KL, Miller C, Hryciuk JE (December 2012). "Female epidemiology of transcription-mediated amplification-based Trichomonas vaginalis detection in a metropolitan setting with a high prevalence of sexually transmitted infection". Journal of Clinical Microbiology. 50 (12): 3927–31. doi:10.1128/JCM.02078-12. PMC 3503002. PMID 23015673.
There were about 58 million cases of trichomoniasis in 2013.[38] It is more common in women (2.7%) than males (1.4%).[39] It is the most common non-viral STI in the U.S., with an estimated 3.7 million prevalent cases and 1.1 million new cases per year.[40][41] It is estimated that 3% of the general U.S. population is infected,[21][42] and 7.5-32% of moderate-to-high risk (including incarcerated) populations.[43][44][45][46][47][48][49][50]
The advent of new, highly specific and sensitive trichomoniasis tests present opportunities for new screening protocols for both men and women.[24][27] Careful planning, discussion, and research are required to determine the cost-efficiency and most beneficial use of these new tests for the diagnosis and treatment of trichomoniasis in the U.S., which can lead to better prevention efforts.[24][27]
×